Sermorelin

Sermorelin is a synthetic peptide composed of the first 29 amino acids of the natural GHRH (growth hormone–releasing hormone, 1‑44) sequence — the biologically active segment responsible for receptor binding and signaling. It engages the GHRH receptor on pituitary somatotroph cells, activating intracellular signaling (e.g., adenylate cyclase and cAMP pathways) to stimulate growth hormone synthesis and release in preclinical experimental models.

At Sana, Sermorelin is manufactured with strict quality control to ensure high purity, stability, and consistent batch performance. This compound is intended for laboratory and educational research focused on endocrine signaling, peptide receptor pharmacology, and somatotropic axis dynamics.

Biochemical Characteristics

Sequence: Tyr-DL-Ala-DL-Asp-DL-Ala-DL-xiIle-DL-Phe-DL-xiThr-DL-Asn-DL-Ser-DL-Tyr-DL-Arg-DL-Lys-DL-Val-DL-Leu-Gly-DL-Gln-DL-Leu-DL-Ser-DL-Ala-DL-Arg-DL-Lys-DL-Leu-DL-Leu-DL-Gln-DL-Asp-DL-xiIle-DL-Met-DL-Ser-DL-Arg
Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular Weight: 3357.933 g/mol
PubChem CID: 16129620

As a GHRH-family peptide analogue, sermorelin is used in biochemical workflows to evaluate ligand–receptor interactions, sequence–activity relationships, and stability/handling variables relevant to experimental design. Functional readouts are commonly generated in cell-based assays (e.g., receptor activation and downstream signaling) or in animal models where endocrine-axis activity can be quantified via established laboratory endpoints.

Research Applications

Sermorelin is supplied for research workflows that may include (non-exhaustive):

• GHRH receptor (GHRHR) pharmacology, including ligand binding and receptor-selectivity studies
• cAMP/PKA signaling and downstream transcriptional regulation in somatotroph-derived or engineered receptor-expression systems
• GH/IGF-axis pathway mapping in controlled preclinical models (molecular and tissue-level endpoints)
• Neuroendocrine signaling studies assessing hypothalamic peptide networks and sleep/feeding-related signaling mediators
• Exploratory in-vivo model work evaluating remodeling signatures (e.g., extracellular matrix turnover, angiogenesis markers, and inflammatory mediator profiles) under controlled experimental conditions

Pathway / Mechanistic Context

Mechanistically, GHRH-family ligands signal through the growth hormone–releasing hormone receptor (GHRHR), a class B G protein–coupled receptor. In canonical models, receptor engagement is associated with activation of adenylate cyclase and elevation of intracellular cAMP, supporting PKA-dependent phosphorylation events and regulated gene expression programs relevant to somatotroph function.

Downstream signaling contexts frequently evaluated in preclinical systems include pathway cross-talk with MAPK/ERK and PI3K/Akt signaling nodes, which are commonly studied for their roles in cell survival, differentiation programs, and stimulus-dependent transcriptional outputs. In tissue models, downstream readouts may include extracellular matrix (ECM) turnover markers, vascular remodeling/angiogenesis signatures, and cytokine/chemokine profiles measured using standard laboratory assays.

Preclinical Research Summary

GHRH-Analogue Signaling in Cardiac Remodeling Models

Preclinical large-animal studies have evaluated GHRH-analogue signaling in controlled ischemic injury models. Reported experimental endpoints include remodeling-associated measures such as apoptosis-associated markers, extracellular matrix organization, and microvascular/capillary density in peri-injury tissue regions, along with inflammatory mediator profiling in myocardial tissue^[1], ^[2].

These investigations are typically used to inform mechanistic remodeling biology experiments (e.g., ECM deposition/turnover, angiogenesis-related gene expression, and inflammatory signaling changes) in vitro and in vivo, and are presented here solely as preclinical pathway context.

GHRH-Analogue Activity in Experimental Seizure Models

Rodent epilepsy models have been used to explore interactions between GHRH analogues and inhibitory neurotransmission systems. Published work has examined relationships between GHRH-family signaling and GABA receptor biology in brain tissue and experimental seizure paradigms, supporting mechanistic evaluation of receptor cross-talk in neurophysiological signaling networks_[3].

Neuroendocrine Axis Coupling in Sleep-Related Signaling

Sleep–wake regulatory pathways are frequently investigated through neuropeptide systems, including orexin/hypocretin networks. In fish models, studies have assessed endocrine coupling between GHRH-axis activity and orexigenic signaling, providing a basis for mechanistic experiments examining neuroendocrine coordination and peptide–receptor signaling integration under controlled laboratory conditions^[4].

Receptor Regulation and Desensitization Concepts in Peptide Signaling

Experimental frameworks for peptide ligands frequently assess receptor regulation phenomena (e.g., desensitization, internalization, and signaling bias) using established in-vitro models and systems-level readouts. Literature discussing receptor response dynamics and tachyphylaxis/desensitization concepts is frequently used to inform receptor pharmacology experiment design and interpretation of longitudinal signaling measurements in controlled settings^[5], ^[6].

All research summaries above reflect preclinical and laboratory observations and are provided solely to support experimental planning and mechanistic discussion.

Form & Analytical Testing

Sermorelin supplied for research is typically prepared as a synthetic peptide for laboratory handling and downstream analytical verification. Product identity and purity are commonly confirmed using chromatographic and mass spectrometric methods. Batch-specific analytical documentation is provided below.

Article Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Richard F. Walker, Ph.D, R.Ph, lead author of A better approach to management of adult-onset growth hormone insufficiency?”, received a BS in pharmacy from Rutgers University, a MS in Biochemistry from New Mexico State University and a PhD in a physiology from Rutgers University. He holds postdoctoral fellowships in neuroendocrinology and neuropharmacology at Duke University College of Medicine (Center for the Study of Aging and Human Development) and the University of California, Berkeley, respectively.

Richard F. Walker, Ph.D, R.Ph is being referenced for academic attribution purposes. No endorsement, affiliation, or commercial relationship is implied or expressed between any researcher and any product offering. The purpose of citing the author is to acknowledge published scientific contributions. Richard F. Walker, Ph.D, R.Ph is listed in [5] under the referenced citations.

Referenced Citations

1. L. Bagno et al., “Growth Hormone–Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute Ischemic Cardiomyopathy,” J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis., vol. 4, no. 4, Mar. 2015.
2. M. Kanashiro-Takeuchi et al., “New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor,” Oncotarget, vol. 6, no. 12, pp. 9728–9739, Mar. 2015.
3. Tang et al., “Interactions between GHRH and GABAARs in the brains of patients with epilepsy and in animal models of epilepsy,” Sci. Rep., vol. 7, Dec. 2017.
4. S. Shepherd et al., “Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss),” Comp. Biochem. Physiol. A. Mol. Integr. Physiol., vol. 146, no. 3, pp. 390–399, Mar. 2007.
5. F. Walker, “Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?,” Clin. Interv. Aging, vol. 1, no. 4, pp. 307–308, Dec. 2006.
6. T. Wahid, P. Marbach, B. Stolz, M. Miller, R. A. James, and S. G. Ball, “Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues,” Eur. J. Endocrinol., vol. 146, no. 3, pp. 295–302, Mar. 2002.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

RUO Disclaimer

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.

Storage Information

• Store in a cool, dry environment

• Protect from light and moisture

• Keep vial tightly sealed when not in use

• Handle using standard laboratory safety protocols